A Case Study to Assess the Risk of Cardio metabolic Side Effects in Patients Receiving Atypical Antipsychotics Particularly Resperidone and Clozapine
Author(s): P Kanmani*, Sankar A, Umashankar, Aravind Raj S, Goutham kumar A P and K Padmalatha
Abstract
The Atypical antipsychotics (AAPs) are usually associated with increased risk of weight gain and increased incidence of metabolic side effects particularly impaired glucose tolerance, weight gain, dyslipidemia. Epidemiological, cross-sectional and prospective studies suggest that two of the AAPs, resperidone and clozapine, cause the most dramatic weight gain and metabolic impairments including increased fasting glucose, insulin resistance incidence and raised triglycerides levels. Comparing to other AAPs both resperidone and clozapine exhibit a particularly high antagonistic affinity for histamine and muscarinic receptors which have been the main cause reported for increase in weight gain and the development glucose abnormalities. In this study we studied about the cardiovascular and metabolic abnormalities (such as obesity, hyperglycemia, dyslipidemia and metabolic syndrome).